0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BCMA

BCMA

BCMA Molecule Information

Name:B-cell maturation protein
Target Synonym:B-Cell Maturation Antigen,B-Cell Maturation Protein,B-Cell Maturation Factor,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,B Cell Maturation Antigen,BCMA,BCM,TNF Receptor Superfamily Member 17,CD269,TNFRSF13A,Tumor Necrosis F
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:42
Lastest Research Phase:Approved

BCMA Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
BCA-HF2H3 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag Star Staining
BCA-HF2H3-structure
BCA-HF2H3-sds
BCA-C52H3 Canine Canine BCMA / TNFRSF17 Protein,His Tag (MALS verified)
BCA-C52H3-structure
BCA-R52H3 Rat Rat BCMA / TNFRSF17 Protein,His Tag
BCA-R52H3-structure
BCA-R52H4 Rabbit Rabbit BCMA / TNFRSF17 Protein,His Tag
BCA-R52H4-structure
BCA-HP2H2 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)
BCA-HP2H2-structure
BCA-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His,Avitag™
BCA-C82E5-structure
BCA-C82E5-sds
BCA-C82E5-elisa_1
BCA-M43 Mouse Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43-sds
BCA-M43-elisa_1
BCA-M43-elisa_2
MBS-K004 Human Human BCMA-coupled Magnetic Beads
MBS-K004-elisa_1
BCA-HF2H1 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag DMF Filed
BCA-HF2H1-structure
BCA-HF2H1-sds
BCA-H5253 Human Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin
BCA-H5253-structure
BCA-H5253-sds
BCA-H5253-elisa_1
BCA-M52H3 Mouse Mouse BCMA / TNFRSF17 Protein, His Tag
BCA-M52H3-structure
BCA-M52H3-sds
BCA-M52H3-elisa_1
BCA-H82E4 Human Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™ DMF Filed
BCA-H82E4-structure
BCA-H82E4-sds
BCA-H82E4-elisa_1
BCA-H5259 Human Human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin
BCA-H5259-structure
BCA-H5259-sds
BCA-H5259-elisa_1
BCA-C52H7 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag
BCA-C52H7-structure
BCA-C52H7-sds
BCA-C52H7-elisa_1
BCA-M82F0 Mouse Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-M82F0-structure
BCA-M82F0-sds
BCA-M82F0-elisa_1
BCA-M5258 Mouse Mouse BCMA / TNFRSF17 Protein, Fc Tag
BCA-M5258-structure
BCA-M5258-sds
BCA-M5258-elisa_1
BCA-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag
BCA-C5253-structure
BCA-C5253-sds
BCA-C5253-elisa_1
BCA-C82F4 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-C82F4-structure
BCA-C82F4-sds
BCA-C82F4-elisa_1
BC7-H82F0 Human Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™ DMF Filed
BC7-H82F0-structure
BC7-H82F0-sds
BC7-H82F0-elisa_1
BCA-H522y Human Human BCMA / TNFRSF17 Protein,His Tag (HPLC-verified) DMF Filed
BCA-H522y-structure
BCA-H522y-sds
BCA-H522y-hplc
BCA-H522y-elisa_1
BCA-H522y-elisa_2
BCA-HF254 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag DMF Filed
BCA-HF254-structure
BCA-HF254-sds
BCA-HF254-elisa_1
BC7-H5254 Human Human BCMA / TNFRSF17 Protein, Fc Tag (HPLC verified) DMF Filed
BC7-H5254-structure
BC7-H5254-sds
BC7-H5254-hplc
BC7-H5254-elisa_1

BCMA Part of Bioactivity data

BCA-HF2H3-Cell-based assay
Evaluation of CAR expression

2e5 of 293 CAR cells transfected with anti-BCMA-scFv were stained with 100 μL of 1 μg/mL of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), FITC signal was used to evaluate the binding activity (QC tested).

BCA-M43-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCA-H522y-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 13.0 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCMA Customer Reviews

Synonym Name

TNFRSF17,CD269,BCM,BCMA

Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Clinical and Translational Updates

BCMA Related Molecule

BCMA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Idecabtagene vicleucel bb-2121 Approved Bluebird Bio Abecma United States Multiple Myeloma s:12:"Celgene Corp"; 2021-03-26 Multiple Myeloma Details
Belantamab mafodotin GSK-2857916; GSK2857916 Approved Glaxosmithkline Plc BLENREP EU Multiple Myeloma s:29:"Glaxosmithkline (Ireland) Ltd"; 2020-08-05 Multiple Myeloma Details

BCMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LCAR-B4822M LCAR-B4822M Phase 1 Clinical Genscript Biotech Corp Multiple Myeloma Details
SEA-BCMA SEA-BCMA; SGN-BCMA Phase 1 Clinical Seattle Genetics Multiple Myeloma Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase 1 Clinical Arcellx Multiple Myeloma Details
CTX-120 CTX-120 Phase 1 Clinical Crispr Therapeutics Multiple Myeloma Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) Phase 1 Clinical Multiple Myeloma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
TNB-383B TNB-383B Phase 1 Clinical Teneobio Multiple Myeloma Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Phase 1 Clinical Multiple Myeloma Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 1 Clinical The First Affiliated Hospital Of Nanchang University Multiple Myeloma Details
GC-012F GC-012F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Multiple Myeloma Details
P-BCMA-101 P-BCMA-101 Phase 2 Clinical Poseida Therapeutics Multiple Myeloma Details
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Phase 2 Clinical Asclepius Technology Company Group Multiple Myeloma Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) Clinical Wuhan Bio-Raid Biotechnology Hematologic Neoplasms Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) Phase 3 Clinical The First Affiliated Hospital Of Soochow University Multiple Myeloma Details
CC-98633 CC-98633 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) FCARH-143; ET140-CAR; MCARH-171; JCARH-125; ET-140 Phase 2 Clinical Juno Therapeutics Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) CBG-002 CAR-T Phase 1 Clinical Multiple Myeloma Details
HBI-0101 HBI-0101 Hadassah Medical Organization Details
CC-99712 CC-99712 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
KITE-585 KITE-585 Phase 1 Clinical Kite Pharma, National Cancer Institute Multiple Myeloma Details
PBCAR-269A PBCAR-269A Phase 2 Clinical Precision Biosciences Multiple Myeloma Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) Phase 1 Clinical Sichuan University Multiple Myeloma Details
CC-93269 EM-901; CC-93269 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
Allogeneic anti-BCMA CAR-T (Legend) Phase 1 Clinical Multiple Myeloma Details
Anti-BCMA/CD19 CAR-T(Autolus) Details
CAR-BCMA T cell therapy CT-053-CARsgen Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Multiple Myeloma Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase 1 Clinical Hrain Biotechnology Co Ltd Multiple Myeloma Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell Details
REGN-5459 REGN-5459 Phase 2 Clinical Regeneron Pharmaceuticals Inc Multiple Myeloma Details
ALLO-715 ALLO-715 Phase 1 Clinical Cellectis, Allogene Therapeutics Inc Multiple Myeloma Details
AMG-420 AMG-420; BI-836909 Phase 1 Clinical Micromet Multiple Myeloma Details
bb-21217 bb-21217 Phase 1 Clinical Bluebird Bio Multiple Myeloma Details
MEDI-2228 MEDI-2228 Phase 1 Clinical Medimmune Llc Multiple Myeloma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) CT-103A; CT103A; IB1-326; IB1326 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd Multiple Myeloma Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) Phase 1 Clinical Shandong New Time Pharmaceutical Co Ltd Multiple Myeloma Details
BCMA CAR-T Cells (Pregene) PRG-1801 Phase 1 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd Multiple Myeloma Details
Pavurutamab AMG-701 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) Clinical Multiple Myeloma Details
JWCAR129 JWCAR129 Phase 1 Clinical The First Affiliated Hospital Of Soochow University Details
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) Bioray Laboraytories Inc Details
HPN-217 HPN-217 Phase 2 Clinical Harpoon Therapeutics Multiple Myeloma Details
Teclistamab JNJ-64007957; JNJ-64007959; JNJ-7957 Phase 2 Clinical Genmab, Janssen Global Services Llc Hematologic Neoplasms; Multiple Myeloma Details
ACTR 087/SEA BCMA combination therapy Phase 1 Clinical Unum Therapeutics Multiple Myeloma Details
EMB-06 EMB-06; EMB06 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Multiple Myeloma Details
ALLO-605 ALLO-605; ALLO605 Phase 2 Clinical Multiple Myeloma Details
Elranatamab PF-06863135 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Multiple Myeloma Details

This web search service is supported by Google Inc.

totop